Largest biotech by total assets
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total assets, at PLN 364.1B, ahead of Gilead Sciences (PLN 237.2B) and Biogen (PLN 118.3B). Figures as of 18 Nov 2026, 13:57 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenPLN 364.1B
- Median
- PLN 10.3B
- Combined market value
- PLN 3.41T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | PLN 364.1B | PLN 995.6B | PLN 1,840.60 | 0.95% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | PLN 237.2B | PLN 848.8B | PLN 684.34 | 1.60% up | 33% up | ||
| 3 | BiogenBIIB · Health Care | PLN 118.3B | PLN 149B | PLN 1,008.03 | 0.34% down | 49% up | ||
| 4 | BioNTechBNTX · Health Care | PLN 98.1B | PLN 84.6B | PLN 341.09 | 0.47% down | 16% down | ||
| 5 | ModernaMRNA · Health Care | PLN 49.6B | PLN 336.3B | PLN 831.21 | 3.93% down | 755% up | ||
| 6 | argenxARGX · Health Care | PLN 34.9B | PLN 239.5B | PLN 3,808.46 | 0.36% down | 4% up | ||
| 7 | QiagenQGEN · Health Care | PLN 25.2B | PLN 41.3B | PLN 199.97 | 0.12% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | PLN 18.6B | PLN 67.5B | PLN 666.90 | 0.37% up | 20% up | ||
| 9 | VaxcytePCVX · Health Care | PLN 12.1B | PLN 37.8B | PLN 238.75 | 3.59% down | 22% up | ||
| 10 | RepligenRGEN · Health Care | PLN 11.9B | PLN 41.7B | PLN 651.87 | 0.37% down | 5% up | ||
| 11 | ExelixisEXEL · Health Care | PLN 11.4B | PLN 67.2B | PLN 275.33 | 2.09% up | 63% up | ||
| 12 | Bio-TechneTECH · Health Care | PLN 10.4B | PLN 45.9B | PLN 291.93 | 0.22% down | 26% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | PLN 10.2B | PLN 44B | PLN 385.74 | 0.55% down | 37% up | ||
| 14 | Revolution MedicinesRVMD · Health Care | PLN 9.5B | PLN 141.4B | PLN 653.92 | 2.50% down | 131% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | PLN 9.1B | PLN 15.7B | PLN 161.38 | 0.54% down | 21% down | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | PLN 7B | PLN 41.7B | PLN 488.44 | 3.44% down | 87% up | ||
| 17 | Krystal BiotechKRYS · Health Care | PLN 5.4B | PLN 35.6B | PLN 1,199.99 | 0.22% up | 46% up | ||
| 18 | ImmunovantIMVT · Health Care | PLN 3.8B | PLN 27.6B | PLN 133.48 | 0.21% down | 43% up | ||
| 19 | CG OncologyCGON · Health Care | PLN 3.2B | PLN 28.3B | PLN 317.29 | 6.89% down | 85% up | ||
| 20 | Twist BioscienceTWST · Health Care | PLN 2.6B | PLN 30.7B | PLN 450.17 | 6.63% up | 340% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | PLN 2.1B | PLN 18.5B | PLN 114.51 | 2.22% up | 88% up | ||
| 22 | ImmunityBioIBRX · Health Care | PLN 2B | PLN 26.8B | PLN 25.16 | 4.68% up | 193% up | ||
| 23 | Scholar Rock HoldingSRRK · Health Care | PLN 1.6B | PLN 22.1B | PLN 181.19 | 1.21% up | 14% up | ||
| 24 | Kodiak SciencesKOD · Health Care | PLN 1.4B | PLN 25.4B | PLN 389.08 | 3.90% down | 396% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0194 PLN).
Questions and answers
Which biotech rank first by total assets?
Amgen (PLN 364.1B), Gilead Sciences (PLN 237.2B) and Biogen (PLN 118.3B) are the top three of the 24 biotech ranked by total assets as of 18 Nov 2026, 13:57 UTC.
How many biotech are in this ranking?
24 are ranked by total assets.
What are these biotech worth together?
The 24 biotech ranked by total assets have a combined market value of PLN 3.41T as of 18 Nov 2026, 13:57 UTC.
What does ranking by total assets measure?
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-assets
Underlying data: Yahoo Finance; SEC EDGAR.